Audit: QRS - Saccharin for Health & Longevity

Audit conducted on 10/31/2026 06:36 using AI4L / Opus 5.5

Iterations

Summary

Items	Count
Total	97
Passed	88
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Lede, protocol, gates, tiers, monitoring and cadence all trace to ER text (e.g., lede vs Conclusion lines 404-408; action_2_sub vs line 323).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Hedges kept: “Any weight effect” (time_2_sub), “No established target; track change from own baseline” (marker_4_target), “Proof … is missing” in lede.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	No strengthening or softening found; contraindications listed as avoid, matching ER “Populations who should avoid”.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Items stay in their ER categories; modifying factors are not surfaced as cautions or side effects.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, citations, expert names, NCT IDs or brand names appear.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, evidence-weighing tone mirrors the ER.
2.2	The tone of the QRS is expert, accessible, objective, and data-driven	🟢	Expert, objective, data-driven phrasing.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Presents ER facts without prescribing.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Footer disclaimer kept; no clinical directives beyond ER protocol content.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Protocol cells present ER content; no recommending language.
2.6	The QRS never addresses the reader directly — it presents evidence, not guidance	🟢	No second-person address.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms (HbA1c, OGTT, CGM, tubular secretion) are ER labels carried verbatim.
2.8	Information is presented in a concise and very compact manner	🟢	Compact items throughout.
2.9	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Content (ADI ceilings, glucose-response testing) fits a proactive, health-optimizing audience.
2.10	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Monitoring cadence with OGTT/CGM retesting assumes an effort-willing audience.
2.11	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Not pitched to the general population.
2.12	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Weighting follows ER: substitution benefit High, weight benefit Low, observational harms Medium.
2.13	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	No “anti-aging” wording.
2.14	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	Formal terminology; “two capsules”, “Oral antibiotics” are ER wording; no lay route phrasing.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings, gate headings, tier labels and column headers match the template (lines 446, 483, 525, 545, 556, 583, 602, 606-608, 688).
3.2	Every element carrying a data-qrs-var attribute in [qrs_template] is present in the QRS with the same name	🟢	All template data-qrs-var names present; marker_# and qualitative_item_# expanded to numbered names per 14.2/15.2.
3.3	Everything outside the data-qrs-var spans — markup, text, styles, comments — is as in the template; spans that no checklist item addresses are left unchanged as well	🟢	Diff against template shows changes only inside data-qrs-var spans and the filled metadata block (pipeline keys duration/git_user/git_issue added there).

4. Formatting

#	Description	Result	Comments
4.1	An empty ER section never produces visible empty-state text in the QRS: the corresponding region is hidden or left empty. Phrases such as “None documented in human trials to date” or “Not formally studied” appear only where the ER uses them for a fact the QRS carries over.	🟢	No empty-state text; empty tiers and time_3 hidden. “Not specified in the ER” (marker_6_target) is required by 14.3.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Action labels “Substitution approach”, “Intake ceilings differ by regulator”, “Trial doses” are verbatim ER bold labels (lines 322-325).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Labels verbatim or trimmed from ER wording; example lists trimmed with ER’s own words.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji indicators in the QRS.
4.5	The QRS is designed to render on one A4 page. It fails this item only for one of four things: a trailing clause after a dash, an optional gloss, an example list left untrimmed, or a repetition. Nothing else is cut to fit.	🟢	No trailing dash clauses, glosses, untrimmed example lists or repetitions found.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Metadata comment directly follows <!doctype html> (lines 1-14).
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	YAML delimited by — lines 3 and 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Inside an HTML comment; not surfaced elsewhere.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Values trimmed; only duration “00:02” quoted, which contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: saccharin_2026-1031-0241_Opus_ER.md
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.10.25 matches QRS.md version.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-1031-0627
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus
5.9	The nickname of the AI is the full name without the version number, with all remaining words joined by hyphens (e.g., Opus, Sonnet, Grok, Gemini-Flash, GPT); when the full name has no version number or is “Unknown”, the nickname equals the full name	🟢	Opus = Opus 5.5 without version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5.5
5.11	The full name of the AI consists of the model name (the word or words directly before the version number, leaving out the first if there is more than one, e.g., Claude Opus 5.5 → Opus 5.5), the model version number and the variant (if any) as stated in the system prompt or developer instructions of the creating model, with every word capitalized and without product, effort or pricing names (e.g., Opus X.Y, Sonnet X.Y, Grok X.Y, Gemini X.Y Flash, GPT X.Y), the model name alone when the system prompt or developer instructions name a model without a version number (e.g., Grok), or “Unknown” when neither the system prompt nor the developer instructions of the creating model name a model	🟢	“Opus 5.5” follows the name-version format.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: saccharin_2026-1031-0241_Opus_QRS.html matches the file.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Saccharin for Health & Longevity - Quick Reference Sheet” (line 21).
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	“Saccharin for Health & Longevity” (line 423).
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	10/31/2026 matches 2026-1031-0627.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Opus 5.5 (line 431).
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	No extra header content.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢	Opens “Saccharin, the oldest calorie-free manufactured sweetener, replaces table sugar” before any verdict.
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses the ER Conclusion’s benefit, weight, cancer, cognition/mortality and open-question points.
7.3	[at_a_glance] is no longer than 70 words	🟢	67 words.
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each fact maps to ER Motivation/Conclusion passages (lines 38, 404-408).
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms or specialist terms.
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, sample sizes or p-values.
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No effect sizes or statistics.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Items from ER “Populations who should avoid Saccharin” (lines 297-302).
8.2	[stop_items] represent the Contraindications from the ER	🟢	All four ER populations listed (lines 548-551).
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Each item an <li>.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Bare key facts, rationale and citations stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Staging qualifier “Advanced” kept for chronic kidney disease.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER uses no ranking notation in contraindications.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	Section populated; ER names populations to avoid.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!-- empty: ER names no population that should avoid the intervention -->	N/A	Section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Derived from ER Key Interactions & Contraindications (lines 285-295).
9.2	[caution_items] represent the ER’s documented interactions — the items under its “Documented interactions:” label — excluding any that are already listed as Contraindications and any entry phrased as no interaction found	🟢	Probenecid listed; lactisole (“no interaction found”) correctly excluded.
9.3	[caution_theoretical_items] represent the ER’s theoretical interactions — the items under its “Theoretical interactions (inferred from mechanism, not studied in humans):” label	🟢	All four ER theoretical interactions listed (lines 569-572).
9.4	The ER placeholder “None identified” is never an item: it means that group is empty	🟢	No “None identified” item.
9.5	Individual [caution_items] and [caution_theoretical_items] are formatted as <li></li>. The template’s bold “Theoretical (inferred from mechanism)” sub-heading is the only marker of the second list’s status: no item carries “(theoretical)”, “inferred from” or a mechanism clause	🟢	All items are <li>; none carries a theoretical marker or mechanism clause.
9.6	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	No trailing clauses, rationale or citations.
9.7	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example lists kept, trimmed to ER’s own words (e.g., methotrexate, penicillin G; sucralose, acesulfame potassium).
9.8	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER uses no ranking notation in interactions.
9.9	If the ER’s theoretical group is empty, the whole Theoretical block — the caution_theoretical span with its sub-heading and list — is hidden with style="display:none", not removed: its spans stay in place, empty.	N/A	ER theoretical group is not empty.
9.10	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	Section populated; ER identifies interactions.
9.11	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on, and the Theoretical block is hidden per 9.9. E.g. <!-- empty: ER names no interaction that changes how the intervention is used -->	N/A	Section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Therapeutic Protocol section	🟢	All three action sets from ER Therapeutic Protocol (lines 322-325).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from that section	🟢	Substitution approach, intake ceilings and trial doses cover the key how/how-much aspects.
10.3	If fewer than three distinct actionable implementation aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing.	N/A	ER Therapeutic Protocol names more than three actionable aspects.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from that section.	🟢	All label/value/sub cells filled from ER content.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	ER gives two time-to-effect aspects (line 355): immediate sweetness/glucose and months for weight; both used.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Glucose (High benefit) first, weight (Low benefit) second.
11.3	If fewer than three distinct time-to-effect aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing.	🟢	time_3 spans empty and hidden with style=”display:none” (lines 511-517).
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	time_1 and time_2 filled from ER Practical Considerations.
11.5	If the ER provides no information on time to effect at all, the whole Time to effect block (its subhead and all three sets) is hidden with style="display:none", not removed: its spans stay in place, empty.	N/A	ER provides time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Items are ER Expected Benefits headings.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four benefit variables present.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Headings only; no qualifiers or effect sizes.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content.
12.5	If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	benefits_medium hidden with style=”display:none” (line 530).

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Items are ER Potential Risks & Side Effects headings.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four risk variables present.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Headings only; no qualifiers or effect sizes.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content.
13.5	If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	risks_high hidden with style=”display:none” (line 585).

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring Protocol & Defining Success section	🟢	Markers and cadence from ER Monitoring Protocol & Defining Success (lines 372-381).
14.2	All measurable/quantifiable biomarkers from that section are listed, one table row per marker; the template’s # row is the pattern, repeated with # replaced by 1, 2, 3 … in the data-qrs-var names	🟢	Four table biomarkers plus body weight and waist circumference from baseline text; rows numbered 1-6.
14.3	[marker_#name] is the marker, [marker#target] its target value or range as given in the ER, [marker#_why] its purpose in a few words; a target the ER does not give is written “Not specified in the ER”	🟢	Targets as in ER; waist circumference target given as “Not specified in the ER”.
14.4	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from that section. It is not left with placeholder text or empty.	🟢	Cadence matches ER Ongoing monitoring (line 374).
14.5	If the ER names no measurable biomarker, the table is hidden with style="display:none" and the single # row is left as in the template	N/A	ER names measurable biomarkers.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring Protocol & Defining Success section	🟢	Items from ER Qualitative markers (lines 383-389).
15.2	All subjective/qualitative markers from that section are listed, one <li> per marker; the template’s # item is the pattern, repeated with # replaced by 1, 2, 3 …	🟢	All five qualitative markers listed, numbered 1-5.
15.3	If the ER names no qualitative marker, the card’s list is hidden with style="display:none" and the single # item is left as in the template	N/A	ER names qualitative markers.

Issues 10/31/2026 06:36

Pass rate 100.00%. No issues found.

Issues 10/31/2026 06:32

1. 4.5 — Untrimmed theoretical example lists: The theoretical interactions keep full example lists: line 569 “(methotrexate, penicillin G, furosemide)”, line 571 “(toothpaste, mouthwash, cough syrups, chewable tablets)” and line 572 “(sucralose, acesulfame potassium in protein powders and electrolyte mixes)”.

Fixes 10/31/2026 06:32

1. 4.5 — Trimmed theoretical example lists: Shortened the theoretical interaction example lists to “(methotrexate, penicillin G)”, “(toothpaste, mouthwash)” and “(sucralose, acesulfame potassium)”, keeping ER wording.

Issues 10/31/2026 06:30

1. 4.5 / 9.6 — Probenecid gloss retained: The Key Interactions item at line 559 keeps “(uricosuric, a gout drug that blocks kidney acid transport)”, an optional gloss with mechanistic rationale; the key fact is “Probenecid”.
2. 7.2 — Lede omits risk signals: The at_a_glance text at line 439 leaves out the Conclusion’s survey-based links to faster decline in memory and thinking and, in diabetes or prediabetes, higher death rates, underweighting the ER’s risk side.

Fixes 10/31/2026 06:30

1. 4.5 / 9.6 — Probenecid gloss removed: Shortened the Key Interactions item from “Probenecid (uricosuric, a gout drug that blocks kidney acid transport)” to “Probenecid”.
2. 7.2 — Lede risk signals added: Rewrote at_a_glance (67 words) to include the Conclusion’s survey-based links to faster memory decline and, in diabetes or prediabetes, higher death rates, while keeping the sugar-replacement, weight, bladder cancer and gut-bacteria points.